Carboxamide compounds and their use as calpain inhibitors

Patent metadata

Field	Value
Publication number	US-9527811-B2
Application number	US-201414570996-A
Country	US
Kind code	B2
Filing date	Dec 15, 2014
Priority date	May 7, 2009
Publication date	Dec 27, 2016
Grant date	Dec 27, 2016

Abstract

The present invention relates to novel carboxamide compounds and their use for the manufacture of a medicament. The carboxamide compounds are inhibitors of calpain (calcium dependant cysteine proteases). The invention therefore also relates to the use of these carboxamide compounds for treating a disorder associated with an elevated calpain activity.
The carboxamide compounds are compounds of the general formula I

in which R 1 , R 2 , R 3a , R 3b , R 4 , Q, Y, A and X have the meanings mentioned in the claims and the description, the tautomers thereof and the pharmaceutically suitable salts thereof. In particular, the compounds have the general formula Ia and Ib

in which R 1 , r, R 2b , R 3a , R 3b , R 4 , Y and X have the meanings mentioned in the claims, including the tautomers thereof and the pharmaceutically suitable salts thereof. Of these compounds those are preferred wherein Y is a moiety CH 2 —CH 2 , CH 2 —CH 2 —CH 2 , N(R y# )—CH 2 , N(R y# )—CH 2 —CH 2 or CH═CH—CH═, each optionally having 1 or 2H-atoms replaced with identical or different radicals R y , wherein R y and R y# have the meanings mentioned in the claims.

First claim

The invention claimed is:

1. A method for treating a disorder, an impairment or a condition selected from the group consisting of memory impairment, Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis and concomitant damage to the nervous system, acute autoimmune encephalomyelitis, pain, malaria, damage to the heart following cardiac ischemias, damage to the kidney following renal ischemias, and tumors and metastases thereof
the method comprising administering to a subject in need thereof a compound of formula I:

in which indicates a single bond or, if R 4 is absent, indicates a double bond;
R 1 is hydrogen, C 1 -C 10 -alkyl, C 2 -C 10 -alkenyl, C 2 -C 10 -alkynyl, where the last 3 radicals mentioned may be partly or completely halogenated and/or have 1, 2 or 3 substituents R 1a ,
C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 4 -alkyl, where a CH 2 group in the cycloalkyl moiety of the last two radicals mentioned may be replaced by O, NH, or S, or two adjacent C atoms may form a double bond, where the cycloalkyl moiety may further have 1, 2, 3 or 4 radicals R 1b ,
aryl, hetaryl, aryl-C 1 -C 6 -alkyl, aryl-C 2 -C 6 -alkenyl, hetaryl-C 1 -C 4 -alkyl or hetaryl-C 2 -C 6 -alkenyl, where aryl and hetaryl in the last 6 radicals mentioned may be unsubstituted or carry 1, 2, 3 or 4 identical or different radicals R 1c ; where
R 1a is selected independently of one another from the group consisting of OH, SH, COOH, CN, OCH 2 COOH, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkoxy, C 3 -C 7 -cycloalkyloxy, C 1 -C 6 -alkylthio, C 1 -C 6 -haloalkylthio, COOR a1 , CONR a2 R a3 , SO 2 NR a2 R a3 ,
—NR a2 —SO 2 —R a4 , NR a2 —CO—R a5 , SO 2 —R a4 and NR a6 R a7 ;

R 1b is selected independently of one another from the group consisting of OH, SH, COOH, CN, OCH 2 COOH, halogen, phenyl which optionally has 1, 2 or 3 substituents R 1d ,
C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -alkylthio, where the alkyl moieties in the last 3 substituents mentioned may be partly or completely halogenated and/or have 1, 2 or 3 substituents R 1a ,
COOR b1 , CONR b2 R b3 , SO 2 NR b2 R b3 , NR b2 —SO 2 —R b4 , NR b2 —CO—R b5 , SO 2 —R b4 and NR b6 R b7 ,
in addition two R 1b radicals may together form a C 1 -C 4 -alkylene group, or 2 R 1b radicals bonded to adjacent C atoms of cycloalkyl may form together with the carbon atoms to which they are bonded also a benzene ring;

R 1c is selected independently of one another from the group consisting of OH, SH, halogen, NO 2 , NH 2 , CN, COOH, OCH 2 COOH, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy-C 1 -C 4 -alkyl, C 1 -C 6 -alkylthio, where the alkyl moieties in the last 4 substituents mentioned may be partly or completely halogenated and/or have 1, 2 or 3 substituents R 1a ,
C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 7 -cycloalkyloxy, where the cycloalkyl moiety of the last three radicals mentioned may have 1, 2, 3 or 4 R 1b radicals, and where 1 or 2 CH 2 -groups in the cycloalkyl moiety may be replaced by O, NH or S,
aryl, hetaryl, O-aryl, O—CH 2 -aryl, where the last three radicals mentioned are unsubstituted in the aryl moiety or may carry 1, 2, 3 or 4 radicals R 1d , COOR c1 , CONR c2 R c3 , SO 2 NR c2 R c3 , NR c2 —SO 2 —R c4 , NR c2 —CO—R c5 , SO 2 —R c4 , —(CH 2 ) p —NR c6 R c7 with p=0, 1, 2, 3, 4, 5 or 6 and
O—(CH 2 ) q —NR c6 R c7 with q=2, 3, 4, 5 or 6; where

R a1 , R b1 and R c1 are independently of one another H, C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, C 1 -C 6 -alkyl which has 1, 2 or 3 substituents selected from the group consisting of OH, SH, COOH, CN, OCH 2 COOH, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkoxy, C 3 -C 7 -cycloalkyloxy, C 1 -C 6 -alkylthio, and C 1 -C 6 -haloalkylthio, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 7 -heterocycloalkyl-C 1 -C 4 -alkyl, C 1 -C 6 -alkoxy-C 1 -C 4 -alkyl, aryl, aryl-C 1 -C 4 -alkyl, hetaryl or hetaryl-C 1 -C 4 -alkyl, where aryl and hetaryl in the last 4 radicals mentioned are unsubstituted or have 1, 2 or 3 substituents R 1d ,
R a2 , R b2 and R c2 are independently of one another H, C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, C 1 -C 6 -alkyl which has 1, 2 or 3 substituents selected from the group consisting of OH, SH, COOH, CN, OCH 2 COOH, C 1 -C 6 -alkoxy C 1 -C 6 -haloalkoxy, C 3 -C 7 -cycloalkyloxy, C 1 -C 6 -alkylthio, and C 1 -C 6 -haloalkylthio, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 7 -heterocycloalkyl-C 1 -C 4 -alkyl, C 1 -C 6 -alkoxy-C 1 -C 4 -alkyl, aryl, aryl-C 1 -C 4 -alkyl, hetaryl or hetaryl-C 1 -C 4 -alkyl, where aryl and hetaryl in the last 4 radicals mentioned are unsubstituted or have 1, 2 or 3 substituents R 1d ,
R a3 , R b3 and R c3 are independently of one another H, C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, C 1 -C 6 -alkyl which has 1, 2 or 3 substituents selected from the group consisting of OH, SH, COOH, CN, OCH 2 COOH, C 1 -C 6 -alkoxy C 1 -C 6 -haloalkoxy, C 3 -C 7 -cycloalkyloxy, C 1 -C 6 -alkylthio, and C 1 -C 6 -haloalkylthio, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 7 -heterocycloalkyl-C 1 -C 4 -alkyl, C 1 -C 6 -alkoxy-C 1 -C 4 -alkyl, aryl, aryl-C 1 -C 4 -alkyl, hetaryl or hetaryl-C 1 -C 4 -alkyl, where aryl and hetaryl in the last 4 radicals mentioned are unsubstituted or have 1, 2 or 3 substituents R 1d , or
the two radicals R a2 and R a3 , or R b2 and R b3 or R c2 and R c3 form together with the N atom a 3 to 7-membered, optionally substituted nitrogen heterocycle which may optionally have 1, 2 or 3 further different or identical heteroatoms from the group of O, N, and S as ring members,

R a4 , R b4 and R c4 are independently of one another C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, C 1 -C 6 -alkyl which has 1, 2 or 3 substituents selected from the group consisting of OH, SH, COOH, CN, OCH 2 COOH, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkoxy, C 3 -C 7 -cycloalkyloxy, C 1 -C 6 -alkylthio, and C 1 -C 6 -haloalkylthio, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 7 -heterocycloalkyl-C 1 -C 4 -alkyl, C 1 -C 6 -alkoxy-C 1 -C 4 -alkyl, aryl, aryl-C 1 -C 4 -alkyl, hetaryl or hetaryl-C 1 -C 4 -alkyl, where aryl and hetaryl in the last 4 radicals mentioned are unsubstituted or have 1, 2 or 3 substituents R 1d , and
R a5 , R b5 and R c5 have independently of one another one of the meanings mentioned for R a1 , R b1 and R c1 ,
R a6 , R b6 and R c6 are independently of one another H, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, C 1 -C 6 -haloalkyl, C 1 -C 6 -alkyl which has 1, 2 or 3 substituents selected from the group consisting of OH, SH, COOH, CN OCH 2 COOH, C 1 -C 6 -alkoxy C 1 -C 6 -haloalkoxy, C 3 -C 7 -cycloalkyloxy, C 1 -C 6 -alkylthio, and C 1 -C 6 -haloalkylthio, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkyl-C 1 -C 4 -alkyl, C 3 -C 7 -heterocycloalkyl-C 1 -C 4 -alkyl, C 1 -C 6 -alkoxy-C 1 -C 4 -alkyl, CO—C 1 -C 6 -alkyl, CO—O—C 1 -C 6 -alkyl, SO 2 —C 1 -C 6 -alkyl, aryl, hetaryl, O-aryl, OCH 2 -aryl, aryl-C 1 -C 4 -alkyl, hetaryl-C 1 -C 4 -alkyl, CO-aryl, CO-hetaryl, CO-(aryl-C 1 -C 4 -alkyl), CO-(hetaryl-C 1 -C 4 -alkyl), CO—O-aryl, CO—O-hetaryl, CO—O-(aryl-C 1 -C 4 -alkyl), CO—O-(hetaryl-C 1 -C 4 -alkyl), SO 2 -aryl, SO 2 -hetaryl, SO 2 -(aryl-C 1 -C 4 -alkyl) or SO 2 -(hetaryl-C 1 -C 4 -alkyl), where aryl and hetaryl in the last 18 radicals mentioned are unsubstituted or have 1, 2 or 3 substituents R 1d ,
R a7 , R b7 and R c7 are independently of one another H, C 1 -C 6 -alkyl, C 1 -C 6 -haloalkyl, C 1 -C 6 -alkyl which has 1, 2 or 3 substituents selected from the group consisting of OH, SH, COOH, CN, OCH 2 COOH, C 1 -C 6 -alkoxy C 1 -C 6 -haloalkoxy, C 3 -C 7

Assignees

• Abbvie Deutschland
• Abbvie Inc

Inventors

• Mack Helmut
• Kling Andreas
• Jantos Katja
• Moeller Achim
• Hornberger Wilfried
• Hutchins Charles W

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P25/14

  for treating abnormal movements, e.g. chorea, dyskinesia · CPC title